BDM 10:21 AM BioDiem completes recruitment of patients for clinical trial
http://www.asx.com.au/asxpdf/20070430/pdf/3125py0kj04v57.pdf
BioDiem completes recruitment of patients for its clinical trial in
diabetic eye disease
Australian biopharmaceutical development company BioDiem Ltd (ASX:BDM)
announced today it has completed recruitment of 192 patients in a phase I/II clinical trial of its peptide BDM-E in patients with diabetic macula oedema, a leading cause of blindness.
Commenting on this milestone today, BioDiem Chief Executive Officer, Tom Williams said, “It’s pleasing to have completed this significant step in executing the clinical trial. We now expect to report on the result of the trial during Q4, CY 2007.”
asx ann april 30
Add BDM (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
17.0¢ |
Change
-0.010(5.56%) |
Mkt cap ! $241.6M | |||
| Open | High | Low | Value | Volume |
| 17.5¢ | 17.5¢ | 17.0¢ | $51.15K | 292.3K |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 6 | 304333 | 17.0¢ |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| 17.5¢ | 75000 | 2 |
View Market Depth
| Last trade - 14.30pm 24/05/2024 (20 minute delay) ? |
|
|||||
|
Last
17.5¢ |
Change
-0.010 ( 0.00 %) |
||||
| Open | High | Low | Volume | ||
| 17.5¢ | 17.5¢ | 17.0¢ | 255026 | ||
| Last updated 14.30pm 24/05/2024 ? | |||||
| BDM (ASX) Chart |